The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.

The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a prospective cohort of MS patients with standardized collection of demographic, clinical, MRI data and body fluids that can be us...

Full description

Bibliographic Details
Main Authors: Giulio Disanto, Pascal Benkert, Johannes Lorscheider, Stefanie Mueller, Jochen Vehoff, Chiara Zecca, Simon Ramseier, Lutz Achtnichts, Oliver Findling, Krassen Nedeltchev, Ernst-Wilhelm Radue, Till Sprenger, Christoph Stippich, Tobias Derfuss, Jean-François Louvion, Christian P Kamm, Heinrich P Mattle, Christoph Lotter, Renaud Du Pasquier, Myriam Schluep, Caroline Pot, Patrice H Lalive, Özgür Yaldizli, Claudio Gobbi, Ludwig Kappos, Jens Kuhle, SMSC Scientific Board
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4816556?pdf=render